miR-223-3p mediates the diabetic kidney disease progression by targeting IL6ST/STAT3 pathway

Biochem Biophys Res Commun. 2023 Mar 12:648:50-58. doi: 10.1016/j.bbrc.2023.01.045. Epub 2023 Jan 21.

Abstract

Diabetic kidney disease (DKD), the most pervasive complication in diabetic patients, has become a major health threat to the aging population. Our previous miRNA profiling identified hsa-miR-223-3p as a dysregulated miRNA in the DKD samples, which may serve as a biomarker for DKD diagnosis. However, the specific mechanism of miR-223-3p in the pathogenesis of DKD remains to be elucidated. In this study, we first verified that miR-223-3p level was significantly decreased in the in vitro cell model and in vivo db/db DKD model, accompanied with endothelial cell damage. Importantly, inhibiting the expression of miR-223-3p exacerbated high-glucose induced damages in Human Umbilical Vein Endothelial Cells (HUVECs) and Human Renal Glomerular Endothelial Cells (HRGECs), while miR-223-3p overexpression showed the opposite effect. We further demonstrated that miR-223-3p associated with IL6T mRNA and attenuated the progression of DKD by suppressing the downstream STAT3 activation, indicative of the implication of miR-223-3p/IL6T/STAT3 axis in the pathogenesis of DKD.

Keywords: Diabetic kidney disease; Endothelial cell damage; IL6T; miR-223-3p.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Cytokine Receptor gp130 / metabolism
  • Diabetes Mellitus
  • Diabetic Nephropathies* / metabolism
  • Human Umbilical Vein Endothelial Cells / metabolism
  • Humans
  • Kidney / metabolism
  • MicroRNAs* / metabolism
  • STAT3 Transcription Factor / metabolism

Substances

  • Cytokine Receptor gp130
  • IL6ST protein, human
  • MicroRNAs
  • MIRN223 microRNA, human
  • STAT3 protein, human
  • STAT3 Transcription Factor